Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Curr HIV Res. 2009 Sep;7(5):497–503. doi: 10.2174/157016209789346255

Figure 2. Infectious SHIV vaccine protects against heterologous pathogenic SHIV challenge.

Figure 2

Seven controls and two test monkeys were challenged with SHIV-89.6P and monitored for viral load by bDNA analyses. Results from control and test animals are shown in panels A and B, respectively. Animals were also monitored for CD4+ T-cell percentages among CD3+ populations after challenge with SHIV-89.6P (Panels C and D).